Abstracts tagged "Early Rheumatoid Arthritis and patient outcomes"

Abstract Number: 600 • 2018 ACR/ARHP Annual Meeting
Early Versus Delayed Treatment in Patients with Rheumatoid Arthritis (RA) in Routine Care at a Single US Academic Center: Better Response According to MDHAQ (MultiDimensional Health Assessment questionnaire) for Patients Starting Treatment in the Initial 6 Months
Jacquelin R. Chua, Mariam Riad, Sobia Hassan, Najia Shakoor, Joel A. Block and Isabel Castrejón, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Delay in initiation of disease-modifying anti-rheumatic drug (DMARD) therapy may be a major contributing factor toward poor outcomes in patients with rheumatoid arthritis (RA).…
Abstract Number: 2868 • 2013 ACR/ARHP Annual Meeting
Reliability and Validity Of Patient-Reported Joint Counts and Determinants Of Disagreement With The Physician In Recent Onset Rheumatoid Arthritis
Karen Visser¹, Janet E. Pope², Ernest Choy³, Clifton O. Bingham III⁴, Susan J. Bartlett^5,6, Gilles Boire⁷, Carol A. Hitchon⁸, J. Carter Thorne⁹, Boulos Haraoui¹⁰, Diane Tin¹¹, Edward Keystone¹² and Vivian P. Bykerk¹³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, St Joseph Health Centre, London, ON, Canada, ³Section of Rheumatology, Cardiff University, Cardiff, ENGLAND, United Kingdom, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Patient-reported joint counts (JCs) might improve the efficiency and consistency of disease monitoring, self-management and early recognition of changes in disease activity in rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].